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Abstract 
Chemotherapy-induced cognitive dysfunction or “chemobrain”, the subjective experience when 
one has deficits in cognitive function, is a well-established clinical syndrome, has become an 
increasing concern because the number of long-term cancer survivors is growing dramatically. In 
this review, we hypothesize that the administration of chemotherapy agents initiates a cascade of 
biological changes, with short-lived alterations in the cytokine milieu inducing persistent 
epigenetic alterations. These epigenetic changes lead to changes in gene expression, alterations 
in metabolic activity and neuronal transmission that are responsible for generating the subjective 
experience of cognition. This speculative but testable hypothesis should help to gain a 
comprehensive understanding of the mechanism underlying cognitive dysfunction in cancer 
patients. Such knowledge is critical to identify pharmaceutical targets with the potential to 
prevent and treat cancer-treatment related cognitive dysfunction and similar disorders. 
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What is chemobrain? 
   The development of new chemotherapeutic agents and regimens for cancer therapy has led to a 
significantly reduced risk of recurrence and a higher survival rate in several types of cancer, 
particularly in breast cancer. This increase in cancer survivors, however, has led to an increased 
awareness of the chronic adverse effects of cancer chemotherapeutic agents, including 
undesirable effects on noncancerous cells secondary to the intended cytoxicity on cancer cells. 
One consequence of modern cancer therapy is post-chemotherapy related cognitive dysfunction, 
commonly referred to as “chemobrain” [1].  Cognitive dysfunction is the subjective experience 
when one has deficits in their cognitive function. Objectively measured cognitive deficits will be 
referred here as “cognitive impairment”. A significant number, estimated between 18-78% of 
breast cancer patients report dyscognition soon after initiating chemotherapy treatment [2, 3]. 
While it is possible that cancer can cause cognitive dysfunction and impairment on its own [4-7], 
a defining feature of chemobrain is the onset of complaint after treatment initiation, with its 
corresponding assumption of causality. These symptoms are short-term in the majority of 
patients but have been reported to persist for months to years in ~35% of patients in disease-free 
remission [3, 8]. The findings from the International Cognitive Workshop suggested that cancer-
related cognitive dysfunction may be long-term and has been reported to last 5-10 years after 
treatments in the cancer survivors [9-11]. 
 
  While chemobrain is not an uncommon clinical problem, it has been difficult to demonstrate 
clinically significant cognitive impairment. Repeated studies on the effects of chemotherapy 
have been unable to demonstrate cognitive impairment after treatment [12-20]. Studies that have 
shown cognitive impairment, both cross-sectional [21-24] and longitudinal [25-28], demonstrate 
that the impairment is modest, of unclear clinical significance, and correlates poorly with the 
severity of the subjective experience of chemobrain. Despite the paucity of evidence for 
cognitive impairment, patients with chemobrain consistently report clinically important cognitive 
dysfunction that impair their daily function, in particular in regards to attention, concentration, 
forgetfulness, word-finding, multi-tasking, and organization. The clinical presentation of 
chemobrain is notable for the discordance between the subjective experience of cognitive 
dysfunction and objective neuropsychiatric measurements [29].  
    This discordance between dyscognition and impairment been attributed to a variety of possible 
methodological causes, including problems with the subjective assessment of symptoms, 
methodological and sensitivity issues of modern cognitive testing, the difficulty of accurately 
defining both dyscognition and cognitive impairment [29]. To address these methodological 
issues, the International Cognition and Cancer Task Force (ICCTF) recommended 3 main tests 
with suggested clinical cut-points to determine cognitive impairment in patients with cancer and 
treatment [29, 32]. The recommended tests, which measure learning and memory, processing 
speed, and executive function based on findings of the cognitive effects of chemotherapy on the 
frontal cortex, are Hopkins Verbal Learning Test-Revised (HVLT-R), Trail Making Test (TMT), 
and the Controlled Oral Word Association (COWA) of the Multilingual Aphasia Examination. 
These tests with the recommended standard deviation cut-points for assessment of cognitive 
impairment provide adequate sensitivity and psychometric properties to better measure cognitive 
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impairment in patients with cancer and treatments [29, 32]. However, it seems likely that the 
discordance between subjective dyscognition and objective impairment is a defining observation 
of the nature of chemobrain rather than simply being a measurement artifact. 
   Another important feature of chemobrain is its common, but not mandatory, relationship to 
several somatoform symptoms, in particular anxiety, depression  and fatigue, and overall health-
related decline [33]. The clinical picture of chemobrain is that of a patient developing a 
distressing and often disabling alteration in their subjective cognitive abilities that is difficult to 
objectively demonstrate and is temporally related to both the biological and psychological 
consequences of cancer chemotherapy.  
  Currently, chemobrain is hypothesized to be the result of neuronal injury with consequent 
inadequate repair, abnormal brain remodeling, and corresponding neuro-endocrine-
immunological changes [34]. Studies have described alterations in the blood-brain barrier that 
allow increased access of cytotoxic agents to vulnerable neurons. Neuroimaging studies suggest 
that structural and functional changes in the frontal cortex and related white matter tracts, which 
are implicated in executive and memory function, correlate with chemobrain. Alterations in these 
areas have been correlated with subjective and objective change in neurologic function [30, 31, 
35], post-treatment volume loss [36, 37], and partial recovery over time [4, 37, 38]. However, the 
methodology and small sample sizes of these neuroimaging studies do not demonstrate causality 
or neuronal injury [39]. Evidence to support that oxidative stress, neural repair, immunologic, 
and endocrine changes in chemobrain are severely limited. The essential questions underlying 
the validity of the hypotheses underlying the current chemobrain concept, that of direct causality 
and neuronal injury, are not answered by the scientific literature to date.   
 
  The state of the evidence for chemobrain strongly resembles that which is seen in fibromyalgia 
and chronic fatigue syndrome. Like chemobrain, patients with these illnesses experience 
subjective and clinically distressing dyscognition, with attention, concentration, forgetfulness, 
word-finding, multi-tasking, and organization being the most common complaints. Also like 
chemobrain, measurements of objective neuropsychologic function frequently  fail to 
demonstrate impairment and what is seen in positive studies is of small clinical magnitude [40-
42]. The increased recognition of cognitive symptoms in these disorders has led to their inclusion 
in diagnostic criteria [43, 44]. These illnesses also draw support from neuroimaging studies that 
commonly show alterations in the structure and function of frontal cortical regions that are 
passingly similar to those documented in chemobrain [45]. Limited evidence of alterations in 
oxidative stress, neural repair, immunologic, and endocrine changes have also been reported 
[46]. Both of these illnesses have disputed causal triggers, such as trauma in fibromyalgia and 
infection in chronic fatigue syndrome, whose validity is also not answered by the scientific 
literature to date. The clinical and scientific experience of chemobrain is remarkably similar to 
the dyscognition reported in fibromyalgia and chronic fatigue syndrome. However, no 
comparative studies between these dyscognitive states have been performed to date. The 
implications of this observation are that specific chemotherapeutic-related neurologic injury is 
not required to create the somatic experience of chemobrain. 
 
   The discordance between the severity of subjective experience and that of objective 
impairment is the hallmark of somatoform illnesses, such as fibromyalgia and chronic fatigue 
syndrome. A somatoform view of chemobrain would consider it as an atypical yet predictable 
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subjective experience that results from the normal functioning of the brain rather than from an 
injury. In this way, physiologic factors other than direct neurotoxicity from chemotherapeutic 
agents are the critical ones in establishing and maintaining chemobrain. Chemotherapy, or the 
psychological ramifications of cancer treatment, may simply be one of a variety of “triggers” that 
ultimately lead to dyscognition.  
 
   We emphasize that viewing chemobrain as a somatoform illness does not undermine its clinical 
legitimacy or trivialize the patient suffering that comes with it. All human experiences are 
psychosomatic ones whose existence is dependent on discoverable physiological mechanisms 
that are potentially susceptible to therapeutic manipulation. . Rather, accepting the possibility 
that chemobrain is related to that seen in somatoform illness provides a unique opportunity in 
examining the physiologic underpinnings of these illnesses. Do the biologic alterations that 
accompany the discrete, medically-induced physiologic stress of chemotherapy “trigger” long-
term homeostatic change that is causally responsible for the somatoform experience of 
chemobrain? The current state of evidence is insufficient to answer this question; the answer 
would have important ramifications on the causality of all somatoform illness. Here, the authors 
take the position that such a trigger exists. We hypothesize that acute shifts in cytokines related 
to chemotherapy administration lead to epigenetic alterations. These epigenetic changes persist 
after the resolution of the chemotherapy-induced immunologic changes and are primarily 
responsible for creating and maintaining changes in neuroplasticity that underlie the somatoform 
experience of chemobrain. 
 
The relation of alterations in cytokines to dyscognition  
   Although several candidate mechanisms have been hypothesized to explain chemobrain, the 
exact biological pathways remain unknown [3, 47]. It is highly unlikely that a single biologic 
trigger is responsible for the dyscognition observed in cancer patients following chemotherapy. 
However, it seems likely that cognitive symptoms produced by cancers and cancer treatments 
may share a common final biological mechanism [3, 48, 49]. Studies from humans and animal 
models suggest that several cancer-related symptoms may involve the actions of cytokines. 
Cytokines, along with their systemic effects, have a role in cancer development, progression 
[50], and the commonly experienced adverse effects of chemotherapy, such as chemotherapy-
induced peripheral neuropathy [48] and cognitive dysfunction [34, 51]. Cancer patients who 
received immunotherapy of IL-2 or interferon-α (IFN-α) experienced dyscognition, depression 
and fatigue [52]. Cytokines have been demonstrated to induce both dyscognition and cognitive 
impairment (Table 1).  
 
   In cancer patients, there are multiple mechanisms that lead to alterations in the cytokine milieu.  
Cancer itself leads to increases in circulating cytokines and increased cytokine levels before 
treatment has been associated with cognitive decline in cancer patients [49]. Cytokines are also 
modulated by physical and psychological stress in both animals and humans [53]. Both acute and 
chronic stressors have been shown to increase circulating levels of IL-6 and INF-α [54]. Physical 
and psychological stressors that cancer patients experienced after diagnosis, chemotherapy and 
long-term follow-up are important factors that can lead to elevation in the circulating level of 
cytokines. The administration of chemotherapy also can alter cytokines as the medications 
induce tumor cell death and collateral tissue injury. Patients undergoing chemotherapy with 
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taxanes or anthracycline containing regimen for breast, ovarian cancer, and Hodgkin’s disease 
have statistically significant increases in INF-α, IL-1β, IL-6, IL-8, IL-10, and MCP-1 [55-63]. 
Alterations of cytokines in human cancer appear to multifactorial in origin. In an animal model, 
adriamycin directly causes an increase in TNF-α peripherally, which was subsequently detected 
in the brain (hippocampus and cerebral cortex) although neither adriamycin nor its metabolites 
were found to readily cross the blood-brain-barrier BBB [64].  
   While the cytokine alterations in chemotherapy are not homogenous across patients, they do 
have a relationship with dyscognition. Multiple clinical studies have demonstrated that 
administration of a standard dose of chemotherapy causes increases in cytokine levels such as 
TNF-α, IL-6, IL-8, IL-10, and MCP-1in cancer patients and that these changes are more 
prominent in patients who experienced dyscognition (Table 1) [56-59, 65]. While the evidence 
correlating changes in peripheral cytokine levels to dyscognition in chemotherapy patients is 
strong, the mechanisms by which peripheral cytokines exert their cognitive effects are not. It is 
assumed that dyscognition is caused by neuronal alteration. However, most chemotherapeutic 
agents administered systemically do not cross the blood-brain-barrier (BBB). Cytokines in the 
brain are mainly derived by microglia, with smaller contributions from astrocytes, 
oligodendrocytes, and neurons, rather than peripheral sources [66]. It does not appear that 
chemotherapy alone can be implicated in creating central cytokine change. Rather than 
chemotherapy related cytokine changes acting directly on the brain, it has been postulated that 
there is communication between peripheral cytokines and cytokines inside the CNS. This model 
suggests that peripheral cytokines stimulate neuronal and supportive cells to release central 
cytokines, which then act to alter neuronal plasticity [67, 68]. Recent studies show that there is 
significant bidirectional communication between the peripherally released cytokines and the 
cytokines in the brain through (1) active transport into the brain across the BBB [67, 69], (2) 
passive crossing through the leaky regions in the BBB at circumventricular organs [70], (3) 
stimulation of central cytokine release by the peripheral cytokines through the local 
inflammatory network in the brain [71]. Cytokines have also been identified as the mediators 
which bridge the neuroendocrine and immune systems, with the potential to subsequently alter 
neural activity, neurotransmitter metabolism, neuronal and glial cell function, and neural 
repair/regeneration [34, 67, 72-74]. It seems feasible that peripheral cytokine changes can induce 
central cytokine changes, with subsequent alterations in neuronal function.  
 
  The mechanisms by which changes in central cytokines would induce alterations in cognitive 
dyscognition and impairment are entirely unknown. To date there is no scientific evidence to 
support any particular mechanism. However, the authors speculate that the cytokine alterations 
that occur after chemotherapy have an essential role in triggering a cascade of neurological 
events that lead to chemotherapy-induced cognitive decline [75]. Cytokine change may initiate 
alterations in neurotransmitter systems and neuronal integrity by inducing excitotoxic glutamate 
receptor-mediated damage, altering monoaminergic systems (5-HT, DA and NE), GABA, 
acetylcholine, neuropeptides, and nerve growth factors (BDNF), which are directly associated 
with cognitive function and neurodegenerative processes (Figure 1). Chemotherapeutic injury 
may also lead to the over production of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), with the consequence of producing further oxidative stress via the nitric oxide 
(NO) pathway[76-78]. (1) The activated glial cells produce and release local cytokines that was 
associated with an increase in induction of nitric oxide (NO) synthase [64, 77]; (2) the 
overproduction of reactive oxygen species and oxidative stress derived from the NO pathway  
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have been identified as the most frequent cause of DNA damage in neuronal cells [79, 80]; and 
(3) this damage directly leads to cognitive decline and has been found in peripheral lymphocytes 
after chemotherapy in breast cancer patients [81, 82]. Therefore, further characterization of 
cytokine expression after chemotherapy might yield new insight into the development of 
chemobrain that may lead to the development of effective prevention or treatment strategies. 
   
  In summary, there is strong evidence that correlates changes in peripheral cytokines with the 
development of dyscognition in the setting of many if not all commonly used chemotherapeutic 
drugs for different types of cancer [64, 76, 78, 83]. The changes are typically heterogenous, with 
small magnitude of change being seen in multiple cytokines simultaneously. However, the 
mechanisms by which these cytokines elicit change in the central nervous system are still 
unclear. We speculate that a variety of well-defined neuronal mechanisms enable peripheral 
cytokines to induce central cytokine changes [64, 77, 78, 83], which trigger a subsequent cascade 
of neurological events as described below that lead to the experience of chemobrain.  
 
Epigenetics and Genetic changes associated with chemobrain 
    
   Nowadays, it is generally accepted that long-term cellular memory is mediated by epigenetic 
phenomena and global DNA methylation, which are associated with changes in the cytokine 
milieu [84]. Epigenetics encompasses an array of acquired and heritable modifications of DNA 
that regulate gene expression and function without altering the inherited DNA nucleotide 
sequence. Such modifications include DNA methylation and hydroxymethylation, histone 
modification, and non-coding RNA regulation [85]. Emerging studies indicate that epigenetic 
regulation of gene expression is involved in various brain-related disorders, such as addiction, 
depression, stress, and Alzheimer’s disease, that genetics alone cannot entirely explain. [86-89]. 
Recent studies have indicated that epigenetics, in particular DNA methylation and histone 
acetylation, plays critical roles in brain development, memory formation, and more importantly, 
in regulation of learning and memory [90-93]. In patients with drug abuse recalcitrant to 
conventional therapy, long-lasting epigenetic modification has been demonstrated to occur in the 
limbic system that is prone to relapse [87, 94]. Epigenetic alterations are essential mechanisms 
that enable external and internal environmental cues to interact with genes to creating long-
lasting alterations in gene expression, with the potential to alter homeostatic function and 
subjective experience. 
   As detailed above, the various chemotherapy regimens used to treat cancer have a wide range 
of biologic effects. Despite the heterogeneity of chemotherapy and cancer treatment stresses, the 
cognitive difficulties that follow treatment are stereotypical. Also, the metabolic alterations 
induced by chemotherapy, such as alterations in cytokines, tend to be short-lived [95] but the 
experience of dyscognition is often chronic. This suggests that chemobrain dyscognition may 
have a variety of “triggers” that are able to alter a common upstream pathway responsible for 
perpetuating alterations in cognitive perception. It is reasonable to speculate that chemotherapy-
induced reprogramming of the epigenome is the common pathway that leads to persistent 
dyscognition [51]. There is some early evidence to support the role of epigenetic change in 
chemobrain. Learning and memory impairments following CMF (cyclophosphamide, 
methotrexate, 5-fluorouracil) chemotherapy were found to be associated with increased histone 
H3 acetylation and decreased DHAC (Histone deacetylase) activity in the hippocampus in an 
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animal model [96]. This chromatin remodeling leads to a decrease in neural cell proliferation in 
the hippocampus that might be the plausible mechanism in explaining persistent dyscognition 
after chemotherapy exposure as the DNA methylation induced by cytokines is transient and 
reversed in two weeks after cytokines are removed from the environment [97]. Acquired 
alterations in the methylation pattern have also been found in lymphocytes obtained from 
individuals experiencing psychosocial stress [98, 99]. An association between the development 
and persistence of chemotherapy-induced neuropsychological disorders and epigenetic changes 
following chemotherapy treatment was recently shown in breast cancer patients [51]. In that 
study, the transient methylation for a subset of genes seen after chemotherapy only persisted in 
the patients who developed persistent neuropsychological symptoms. Further investigation into 
how cancer treatments induce epigenetic change seems warranted [100]. 
  While the evidence is far from conclusive, the authors hypothesize that the administration of 
chemotherapy agents initiates a cascade of biological changes, with short-lived alterations in the 
cytokine milieu inducing persistent epigenetic alterations (Figure 2). These epigenetic changes 
eventually lead to gene expression changes, altering metabolic activity and neuronal transmission 
that are responsible for generating the subjective experience of cognition. This proposed 
mechanism may also explain the inconsistencies observed from neuroimaging findings in 
patients with mild to moderate self-reported cognitive dysfunction. These neuroimaging 
inconsistencies may explain that persistent cognitive dysfunction is a subtle process triggered by 
cytokine dysregulation and epigenetic changes that arise from the damage in the brain caused by 
chemotherapy.  
Can “chemobrain” be properly studied, prevented or corrected? 
    The causal model above postulates that the act of treating cancer evokes a heterogeneous, but 
clinically relevant, significant alteration of the extracellular cytokine milieu. This abrupt 
immunologic change acts as a trigger that ushers in a series of functional alterations in the 
genome, from =which the symptoms of cognitive dysfunction stem.  
   It is clearly evident that cancer treatment causes people to develop profound alterations in their 
subjective experience of their own cognition. Modern cancer treatment is complex, with 
important physiologic, psychological, and sociocultural dimensions. However, cancer-related 
dyscognition appears to be a distinct phenomenon with the clear onset and extent following 
chemotherapy, which provides an opportunity to conduct pre-clinical and clinical trials to 
prevent or reduce the cognitive toxicities of chemotherapy. There is good evidence that cancer 
treatment causes a “bump” in cytokine levels as early as in the 24hrs after treatment [58]. This 
“bump” is best characterized as a seemingly small but statistically significant increase in the 
concentration of several pro-inflammatory cytokines induced by chemotherapy administration. 
Despite the current evidentiary weaknesses of the cytokine hypothesis, it has several strengths 
that make it attractive to consider. There is powerful evidence that demonstrates that cytokine 
release is a very early response to environmental change and enables downstream physiologic 
changes in organisms.  Conversely, epigenetic changes appear to occur towards the end of 
responses to environmental change and can persist indefinitely. Cytokines do appear to be a 
reasonable agent to induce upstream changes in genetic expression. Furthermore, similar 
cytokine abnormalities have been observed in other cognitive disorders, suggesting that a variety 
of environmental stimuli may trigger a similar chain of events that lead to cognitive dysfunction. 
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However, the greatest strengths of this hypothesis are that it is both testable with modern 
laboratory techniques and meets Karl Popper’s falsification requirements. Current observation 
strongly suggests that the administration of cancer treatment causes cognitive dysfunction. It is 
possible to ethically design experiments in cancer patients where individuals with normal 
cognition are given a discrete physiologic stress that will frequently induce dyscognition. Such 
an approach is not possible in somatoform disorders, in which causality is less clear and potential 
experimental stressors (such as infection and injury) are not ethical to administer to otherwise 
healthy individuals. Whereas it is possible to watch asymptomatic individuals develop 
chemobrain after treatment, it is typically impossible to do such in other dyscognitive disorders. 
Illnesses such as fibromyalgia and chronic fatigue syndrome are typically recognized after the 
clinical symptoms are already present and attempts to understand the contribution of discrete 
triggering events are subject to recall bias. In this way, chemobrain represents a causal model for 
dyscognition in which it is possible to observe the physiologic changes that occur as an 
individual develops dyscognition, in particular changes in cytokines and epigenetics. 
  Further, the cytokine hypothesis suggests a range of potential therapeutic targets. One potential 
approach would be to prevent the acute change in cytokines related to cancer treatment from 
occurring. Agents that inhibit cytokine activity, such as monoclonal antibodies and small 
molecular inhibitors, may confer benefit either alone or as an adjuvant treatment to 
chemotherapy-induced cognitive decline in cancer patients. TNF-α antagonists (etanercept and 
infliximab) have been shown to inhibit fatigue and improve depressive symptoms in patients 
with advanced cancer [101, 102]. P2X7 antagonist that inhibits IL-1β release has been shown to 
reduce depressive-like profiles [103] and neuropathic pain [104] in animal models. Specific p38 
MAPK and NF-kB inhibitors that block inflammatory signaling transduction have generated 
great interest from their use in the treatment of cytokine-induced depressive behavior and 
antidepressant-like effects in animal models. Anti-inflammatory cytokines, IL-10, IL-4 and 
minocycline may also have the potential therapeutic effects on chemotherapy-induced cognitive 
decline by inhibition of proinflammatory cytokine release through modulation of the caspase 
pathways. Even acupuncture may have therapeutic potential considering its effects on 
suppressing proinflammatory cytokines, TNF-α, IL-1β, IL-6, and IL-10 [105, 106]. Acupuncture 
has been often used to alleviate the side effects of cancer treatment, including pain, nausea, hot 
flashes, fatigue, anxiety/mood disorders, and sleep disturbance [107]. A series of interesting 
studies suggest a therapeutic role in dyscognition, for example, acupuncture improved cognitive 
function of patients with mild cognitive impairment (MCI) and various dementia [108-112], with 
clinical improvement correlating with alterations in functional connectivity and resting state 
activity of particular brain regions [110, 112]. Such approaches to the prevention of cancer-
therapy dyscognition are reasonable, currently feasible, and scientifically testable. 
 
  BDNF and its receptor tropomyosin-related kinase receptor type B (TRKB) play a potential role 
in the pathogenesis of neurological and neuropsychological disorders [113]. Epigenetic or 
pharmacological enhancement of BDNF–trkB signaling restores was reported to reverse the 
aging-related cognitive decline [114]. BDNF polymorphisms are associated with impaired 
memory and cognition, along with reduced hippocampal activation as measured by fMRI [115-
117]. Age-related BDNF declines have been reported to be associated with declines in 
hippocampal volume and spatial memory in the elderly [118]. Low BDNF is associated with 
cognitive impairment in patients with schizophrenia [119] and Alzheimer’s disease [120-122]. 
Significantly decreased blood serum BDNF levels have been detected in patients with cognitive 
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impairment due to obstructive sleep apnoea/hypopnoea syndrome [123]. Given its potent effects 
on neuronal function and survival in various cell systems in the CNS, BDNF has been evaluated 
in patients with various neurological disorders, including amyotrophic lateral sclerosis (ALS), 
peripheral neuropathy, Parkinson’s disease and Alzheimer’s disease [113]. However, delivery of 
BDNF remains a substantial challenge for clinical trials because it is a moderately sized and 
charged protein and only minimal amount of BDNF administrated peripherally crosses the BBB 
to reach neurons in the brain. Acupuncture has been reported to increase neurotrophic factors 
[124] and the levels of nerve growth factors in the brain by altering the permeability of the BBB 
[125]. In rats, electric acupuncture enhanced motor recovery after cerebral infarction that was 
associated with increased expression of BDNF in the brain. 
 
   With cytokines acting as a trigger to upstream changes, anti-cytokine therapies may have little 
therapeutic effect once upstream mechanisms responsible for dyscognition have been 
established, given that the most clinically available anti-cytokine antibodies are not readily to 
penetrate the blood–brain barrier. Antibody concentrations in the brain are typically about a 
thousand times lower than in the blood. Therefore, to better prevent development of cognitive 
dysfunction, anti-cytokine therapies would be best used by blocking cytokine production or 
inhibiting cytokine release in the peripheral prior to triggering the consequent events in the CNS 
[64, 77]. However, epigenetic changes are dynamic and the pathological changes caused by 
epigenetic modifications can be reversed prior to the development of permanent symptoms by 
targeting enzymes or other factors that control or maintain the epigenetic status [126]. 
Treatments that seek to reverse casual epigenetic modifications have the potential to be effective. 
Such treatments are still in their infancy. S-adenosyl methionine (SAM) is an important methyl 
group donor required for proper DNA methylation and has been used to treat memory and 
cognitive symptoms in depressed patients [127, 128]. Betaine, another methyl donor, has been 
shown to improve memory in mice memory impairment induced by lipopolysaccharide [129].  
Histone deacetylases (HDACs) inhibitors can also alter epigenetic modifications, which have 
been studied in memory and cognition [130]. In a mouse model, administration of crebinostat, a 
HDAC inhibitor, improves memory [131, 132]. Sirtuins, a class III HDAC inhibitors found in 
red grape skin and wine resveratrol have been found to improve cognitive function in mice [133] 
and are currently under phase II clinical trial (ADAS-Cog, ClinicalTrials.gov; NCT01504854, 
2013).  
   In summary, cognitive dysfunction remains a common and debilitating effect of cancer 
treatment, with no effective prevention and treatment, although a variety of pharmacologic and 
non-pharmacological strategies have been investigated. We present a speculative but testable 
hypothesis of how cognitive dysfunction may occur following chemotherapy. Unlike other 
dyscognitive illnesses, it is both scientifically and ethically feasible to study the onset of 
“chemobrain” by administering a major physiologic stress and observing the biological 
ramifications. It should be possible to gain a comprehensive understanding of the mechanism 
underlying cognitive dysfunction in cancer patients. Such knowledge is critical to identifying 
methods to both prevent and treat cancer-treatment dyscognition and potentially other 
dyscognitive disorders.  
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Figure Legend: 
Figure 1. Schematic representation of cytokine-mediated cascade associated with chemotherapy-induced 
cognitive dysfunction. Peripheral released cytokines can access the brain to initiate local release of 
cytokines (TNF-α, IL-1β, IL-6, and IFN-α) and chemokines (MCP-1) by following mechanisms: (1) 
Passive crossing through the leaky regions in the blood–brain-barrier at circumventricular organs;(2) 
Active transporting cross the blood–brain-barrier; (3) Stimulating the HPA axis independently or 
synergistically by directly binding to the receptors expressed in the HPA axis or indirectly through 
affecting the secretion of ACTH from the hypothalamus , ACTH from the pituitary or glucocorticoids 
from the adrenal cortex; and (4) Stimulation of endothelial cells and perivascular macrophages, 
monocytes and T cells in the brain to produce similar local cytokines/chemokines. To respond to the local 
released cytokines/chemokines, microglia, astrocytes, oligodendrocytes and neurons in the brain produce 
even more the similar types of cytokines/chemokines which in turn to influence neuronal 
neurotransmitters and integrity through (1) Oxidative stress pathways to increase ROS and RNS (reactive 
oxygen and  nitrogen species), which affect the synthesis of monoamines; (2) P38 MAPKs pathway to 
interfere with serotonin and dopamine transports (5-HTT/DAT) function; (3) Affecting glutamate system 
by activation of IDO - QUIN - NMDAR/EAAT to lead to neuronal excitotoxicity; and finally (4) BDNF 
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(brain derived neurotrophic factor) and TrkB pathway to negatively affect neurogenesis and 
neuroplasticity. All the pathways either working alone or synergistically contribute to the development of 
cognitive decline after chemotherapy exposure in cancer patients.  
Figure 2. Schematic illustration of epigenetic modulation and epigenetic therapeutic approaches for 
chemotherapy-induced cognitive dysfunction. Chemotherapy induced reprogramming of the epigenome, 
DNA methylation and histone modification, may be the plausible common pathway leading to persistent 
cognitive dysfunction after exposure of chemotherapeutic agents. Chemotherapeutic agents cause 
cytokine deregulation and may also directly induce epigenetic changes through DNA methylation and 
histone modification. Each of the factors, alone or synergistically, leads to changes in gene expression and 
cell proliferation in the brain, particularly in the hippocampal and prefrontal cortical areas, which may 
eventually lead to the manifestation of persistent cognitive dysfunction after chemotherapy. Therefore, 
therapeutic intervention (1) by tipping the balance of pro- and anti-inflammatory cytokines by 
acupuncture, (2) modification of DNA methylation by SAM and betaine, or histone acetylation by 
sirtuins, or (3) increasing neurotrophic factors, BDNF, level in the brain, might prove to be the therapeutic 
intervention of the future in psychoneurological symptoms induced by chemotherapy exposure.  
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